Compare Johnson & Johnson (JNJ) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Texas Instruments Incorporated — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Texas Instruments Incorporated trades at $283.74 (market cap $263.20B). The key difference: Johnson & Johnson is far larger — about 2.3× Texas Instruments Incorporated's market cap, and Texas Instruments Incorporated pays the higher dividend (2.11%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Texas Instruments Incorporated for 76 Days on average.
| JNJ | TXN | |
|---|---|---|
Market Cap | $618.09B | $263.20B |
Volume | 6,050,983 | 5,850,256 |
Sector | Health | Technology |
52-Week High | $278.43 | $332.35 |
52-Week Low | $186.00 | $153.33 |
Typical Hold Time | 129 Days | 76 Days |
Enterprise Value | $646.37B | $270.25B |
Dividend Yield | 2.09% | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with $94.19B in 2025 revenue, 21.48% net income margin, and consistent earnings beats in recent quarters. Recent analyst coverage shows 52.5% buy ratings with a $286.53 consensus price target, while technical indicators point to key support at $248 and resistance at $258.
JNJ presents a compelling long-term investment case with robust profitability, diversified healthcare portfolio, and dividend stability, though near-term headwinds include patent expirations and competitive pressures. The stock's current valuation at 29.75 P/E appears reasonable given strong cash flow generation and pipeline innovation, with upside potential to analyst targets if execution continues.
Texas Instruments (TXN) trades at $288.20, down 0.26% on the day, with strong technical momentum showing bullish moving averages and key support at $284. The company demonstrates robust fundamentals with 31.11% net margins and 34.97% ROE, though valuation ratios remain elevated with a P/E of 43.8. Recent earnings show mixed results with Q1 and Q2 2026 beats but a Q4 2025 miss, while data center sales growth and dividend payments highlight ongoing shareholder returns.
Outlook remains positive with analyst consensus targeting $325 (13% upside) amid accelerating revenue growth and AI-driven demand. Key risks include premium valuation sensitivity, cyclical semiconductor exposure, and rising debt levels. Institutional sentiment is bullish with 48% buy ratings, supported by strong cash flow generation and strategic positioning in industrial and data center markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
